CHI3L1 and neoplasm: In line with these therapeutic studies, our in vivo study provides strong evidence that the gene silencing of YKL-40 in tumor cells remarkably suppresses tumorigenesis, highlighting a novel and promising therapeutic strategy tailored to the abrogation of angiogenesis and the reinvigoration of anti-tumor immunity.